---
title: "Stepwise DAPT de-escalation vs standard DAPT after drug-coated balloon angioplasty in multivessel"
id: "medrxiv-15-impact-of-stepwise-dual-antiplatelet-therapy-de-escalation-in-patients-with"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-15-impact-of-stepwise-dual-antiplatelet-therapy-de-escalation-in-patients-with"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.31.26361869v1?rss=1"
published_at: "2026-09-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Stepwise DAPT de-escalation vs standard DAPT after drug-coated balloon angioplasty in multivessel
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-15-impact-of-stepwise-dual-antiplatelet-therapy-de-escalation-in-patients-with
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.31.26361869v1?rss=1)
- **Published At:** 2026-09-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This prespecified subgroup analysis of the REC-CAGEFREE II trial assessed outcomes after **drug-coated balloon (DCB)**–only angioplasty in patients with acute coronary syndrome (ACS) who received either stepwise **dual antiplatelet therapy (DAPT)** de-escalation or standard DAPT. - The trial randomized 1,948 exclusively DCB-treated ACS participants across 41 sites in China to stepwise DAPT de-escalation or standard DAPT; this analysis stratified patients by angiographic vessel status (multivessel versus single-vessel disease). - Multivessel disease was present in 720 of 1,948 patients (37.0%). - The primary endpoint was net adverse clinical events (NACE) at 12 months, defined as a composite of all-cause death, stroke, myocardial infarction, revascularization, and BARC type 3 or 5 bleeding. - Patients with **multivessel disease** had a higher 12‑month NACE rate than those with single‑vessel disease (12.5% vs 6.7%); inverse probability of treatment weighting (IPTW) hazard ratio 1.84 (95% CI 1.35–2.51), P < 0.001. - There was no statistically significant interaction between vessel status (multivessel vs single‑vessel) and treatment allocation for NACE (Pinteraction = 0.542), indicating similar relative effects of the two DAPT strategies across subgroups. - In the multivessel subgroup, NACE occurred in 44/368 (12.1%) with stepwise de-escalation and 45/352 (12.9%) with standard DAPT (HR IPTW 0.95, 95% CI 0.62–1.75, P = 0.818). - In the single‑vessel subgroup, NACE occurred in 43/607 (7.1%) with stepwise de‑escalation and 39/621 (6.3%) with standard DAPT (HR IPTW 1.12, 95% CI 0.72–1.70, P = 0.611). - For a prespecified hierarchical secondary endpoint, win-ratio analyses favored stepwise de-escalation in both multivessel and single-vessel subgroups. - Overall conclusion: among ACS patients treated with DCB-only angioplasty, multivessel disease carried higher absolute NACE risk, and stepwise DAPT de-escalation and standard DAPT showed similar risk–benefit profiles in both vessel-status subgroups. - Trial registration: ClinicalTrials.gov NCT04971356. Data availability: available from corresponding author on reasonable request. Ethical approval and informed consent were obtained; details reported in the source.
## Clinical Analysis & Structured Key Points
Impact of stepwise dual antiplatelet therapy de-escalation in patients with multivessel disease undergoing drug-coated balloon angioplasty: insights from the REC-CAGEFREE II trial | medRxiv Skip to main content Impact of stepwise dual antiplatelet therapy de-escalation in patients with multivessel disease undergoing drug-coated balloon angioplasty: insights from the REC-CAGEFREE II trial View ORCID Profile Chao Gao , Yu Zhang , View ORCID Profile Xingqiang He , Ming Yuan , Fangjun Mou , Jingyu Zhou , Hui Chen , Hua Wang , Wenyi Guo , Yanjin Wei , Zhihui Zhang , Tao Yin , View ORCID Profile Cheng Zhang , Zhexun Lian , Bin Zhu , Jianzheng Liu , Ruining Zhang , Guotao Fu , View ORCID Profile Yoshinobu Onuma , Duolao Wang , View ORCID Profile Patrick W. Serruys , View ORCID Profile Fu Yi , View ORCID Profile Ling Tao doi: https://doi.org/10.64898/2026.08.31.26361869 Chao Gao 1 The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Chao Gao For correspondence: woshigaochao{at}gmail.com Yu Zhang 2 Xijing Hospital, Fourth Military Medical University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Xingqiang He 3 Xijing Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Xingqiang He Ming Yuan 2 Xijing Hospital, Fourth Military Medical University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Fangjun Mou 4 Xijing Hospital,Fourth Military Medical University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jingyu Zhou 4 Xijing Hospital,Fourth Military Medical University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hui Chen 5 Beijing Friendship Hospital, Capital Medical University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Hua Wang 6 West China Fourth Hospital Sichuan University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Wenyi Guo 2 Xijing Hospital, Fourth Military Medical University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yanjin Wei 7 Linyi People's Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Zhihui Zhang 8 Southwest Hospital, the First Affiliated Hospital of Army Medical University (Third Military Medical University); Find this author on Google Scholar Find this author on PubMed Search for this author on this site Tao Yin 9 From the Department of Cardiology, Xijing Hospital, the Fourth Military Medical University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Cheng Zhang 10 Qilu Hospital of Shandong University Qingdao; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Cheng Zhang Zhexun Lian 11 The Affiliated Hospital of Qingdao University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Bin Zhu 12 Xijing hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Jianzheng Liu 12 Xijing hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Ruining Zhang 13 The First Affiliated Hospital of The Fourth Military Medical University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Guotao Fu 3 Xijing Hospital; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yoshinobu Onuma 14 University of Galway; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Yoshinobu Onuma Duolao Wang 15 Liverpool School of Tropical Medicine; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Patrick W. Serruys 14 University of Galway; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Patrick W. Serruys Fu Yi 16 Xijing Hospital, The Fourth Military Medical University Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Fu Yi Ling Tao 2 Xijing Hospital, Fourth Military Medical University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Ling Tao Abstract Info/History Metrics Data/Code Preview PDF Abstract BACKGROUND The optimal antiplatelet regimen in patients with acute coronary syndrome (ACS) and multivessel disease undergoing drug-coated balloon (DCB) angioplasty remains unclear. METHODS This was a prespecified subgroup analysis of the REC-CAGEFREE II trial, which was conducted at 41 sites in China and randomized 1948 exclusively DCB-treated participants with ACS to stepwise dual antiplatelet therapy (DAPT) de-escalation or standard DAPT. The primary endpoint was net adverse clinical events (NACE; including all-cause death, stroke, myocardial infarction, revascularization, and BARC type 3 or 5 bleeding) at 12 months. Participants were stratified into multivessel and single-vessel subgroups according to angiographic characteristics. RESULTS Overall, 720/1948 (37.0%) patients had multivessel disease. The multivessel subgroup was associated with a significantly higher risk of NACE compared with the single-vessel subgroup (12.5% versus 6.7%, HR IPTW:1.84, 95%CI:1.35-2.51, P<0.001). No significant interaction was observed between vessel status (multivessel or single-vessel) and treatment allocation with respect to NACE (Pinteraction=0.542). In the multivessel subgroup, NACE occurred in 44/368 (12.1%) and 45/352 (12.9%) in the stepwise de-escalation and standard DAPT groups (HR IPTW:0.95, 95%CI:0.62-1.75, P=0.818), respectively. In the single-vessel subgroup, NACE occurred in 43/607 (7.1%) and 39/621 (6.3%) in the stepwise de-escalation and standard groups (HR IPTW:1.12, 95%CI:0.72-1.70, P=0.611), respectively. For the prespecified hierarchical secondary endpoint, win ratio analyses yielded more wins for stepwise de-escalation in both subgroups. CONCLUSIONS Among patients with ACS undergoing DCB-only angioplasty, those with multivessel disease were associated with a higher risk of NACE than those with single-vessel disease. Stepwise DAPT de-escalation and standard DAPT exhibited similar risk-benefit profiles in both subgroups. Competing Interest Statement PWS reported receiving consulting fees from Sahajanand Medical Technologies, Novartis, Merillife, Xeltis, and Philips/Volcano outside the scope of the submitted work. Chao Gao received funding from the Noncommunicable Chronic Disease-National Science and Technology Major Project of China. Ming Yuan received funding from the Shaanxi Province Key Technology Research Project of China. All other authors declare no competing interests Clinical Trial NCT04971356 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The protocol was approved by the ethics committee of Xijing Hospital (ID: KY20212080-F-1) and all participating sites, and all participants provided written informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The data that support the findings of this study are available from the corresponding author upon reasonable request. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Back to top Previous Next Posted September 02, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Impact of stepwise dual antiplatelet therapy de-escalation in patients with multivessel disease undergoing drug-coated balloon angioplasty: insights from the REC-CAGEFREE II trial Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Impact of stepwise dual antiplatelet therapy de-escalation in patients with multivessel disease undergoing drug-coated balloon angioplasty: insights from the REC-CAGEFREE II trial Chao Gao , Yu Zhang , Xingqiang He , Ming Yuan , Fangjun Mou , Jingyu Zhou , Hui Chen , Hua Wang , Wenyi Guo , Yanjin Wei , Zhihui Zhang , Tao Yin , Cheng Zhang , Zhexun Lian , Bin Zhu , Jianzheng Liu , Ruining Zhang , Guotao Fu , Yoshinobu Onuma , Duolao Wang , Patrick W. Serruys , Fu Yi , Ling Tao medRxiv 2026.08.31.26361869; doi: https://doi.org/10.64898/2026.08.31.26361869 Share This Article: Copy Citation Tools Impact of stepwise dual antiplatelet therapy de-escalation in patients with multivessel disease undergoing drug-coated balloon angioplasty: insights from the REC-CAGEFREE II trial Chao Gao , Yu Zhang , Xingqiang He , Ming Yuan , Fangjun Mou , Jingyu Zhou , Hui Chen , Hua Wang , Wenyi Guo , Yanjin Wei , Zhihui Zhang , Tao Yin , Cheng Zhang , Zhexun Lian , Bin Zhu , Jianzheng Liu , Ruining Zhang , Guotao Fu , Yoshinobu Onuma , Duolao Wang , Patrick W. Serruys , Fu Yi , Ling Tao medRxiv 2026.08.31.26361869; doi: https://doi.org/10.64898/2026.08.31.26361869 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (614) Allergy and Immunology (896) Anesthesia (327) Cardiovascular Medicine (4772) Dentistry and Oral Medicine (474) Dermatology (407) Emergency Medicine (643) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1615) Epidemiology (15838) Forensic Medicine (32) Gastroenterology (1195) Genetic and Genomic Medicine (6984) Geriatric Medicine (727) Health Economics (1057) Health Informatics (4988) Health Policy (1427) Health Systems and Quality Improvement (1738) Hematology (581) HIV/AIDS (1336) Infectious Diseases (except HIV/AIDS) (16245) Intensive Care and Critical Care Medicine (1161) Medical Education (663) Medical Ethics (151) Nephrology (721) Neurology (7196) Nursing (364) Nutrition (1074) Obstetrics and Gynecology (1232) Occupational and Environmental Health (1001) Oncology (3575) Ophthalmology (1038) Orthopedics (393) Otolaryngology (446) Pain Medicine (466) Palliative Medicine (139) Pathology (704) Pediatrics (1774) Pharmacology and Therapeutics (733) Primary Care Research (759) Psychiatry and Clinical Psychology (5836) Public and Global Health (9694) Radiology and Imaging (2389) Rehabilitation Medicine and Physical Therapy (1435) Respiratory Medicine (1243) Rheumatology (635) Sexual and Reproductive Health (767) Sports Medicine (577) Surgery (767) Toxicology (107) Transplantation (303) Urology (286)
## Related Clinical Research

- [Ticagrelor versus Prasugrel After PCI for Acute Coronary Syndrome: Multinational Comparative Effec](https://medichelpline.com/clinical-feed/medrxiv-23-comparative-effectiveness-of-ticagrelor-vs-prasugrel-in-patients-with-acute.md)
- [One-Year Outcomes of the ISAR SUMMIT Polymer-Free Everolimus-Eluting Stent in Real-World PCI](https://medichelpline.com/clinical-feed/medrxiv-15-one-year-safety-and-effectiveness-of-the-isar-summit-polymer-free-everolimus.md)
- [Semaglutide and Primary Prevention of MACCE in Obese Adults with T2DM and Rheumatoid Arthritis](https://medichelpline.com/clinical-feed/pubmed-42334436.md) (DOI: 10.1093/ehjcvp/pvag044)
- [Optimal DAPT Duration After PCI with Contemporary DES: Network Meta-analysis of RCTs](https://medichelpline.com/clinical-feed/plos-one-7-dual-antiplatelet-therapy-duration-after-percutaneous-coronary-intervention.md)
- [Genistein modifies the association between EASIX and estimated 10-year ASCVD risk](https://medichelpline.com/clinical-feed/plos-one-13-interaction-between-genistein-and-the-endothelial-activation-and-stress-index.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.